Valeriy V. Shustov

Valeriy V. Shustov

Auto-generated profile, based on publicly available information

Valeriy V. Shustov

N.V. Sklifosovsky Research Institute for Emergency Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2021 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
AKAlexander Kostin
Alexander Kostin
MLMaria N. Lundgren
Maria N. Lundgren
ABAndrey Y. Bulanov
Andrey Y. Bulanov
ELElena A. Ladygina
Elena A. Ladygina
KCKarina S. Chirkova
Karina S. Chirkova
SPSergey S. Petrikov
Sergey S. Petrikov

27 September 2021 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
AAAlexander Arutyunov
Alexander Arutyunov
PSP. Seferovic
P. Seferovic
IBIgor G. Bakulin
Igor G. Bakulin
NBN. V. Bakulina
N. V. Bakulina
MBM. M. Batyushin
M. M. Batyushin
ДМД. Мораис
Д. Мораис
By the middle of 2021, the official global number of coronavirus disease 2019 (COVID-19) patients was close to 230 million, but the number accounting for asymptomatic patients was much higher. Consequences and rehabilitation after COVID-19 are of particular interest and raise many controversial and unresolved issues. On May 18, 2021, the Eurasian Association of Therapists organized an international panel of experts to analyze challenges associated with the post-COVID-19 period. This panel aimed to develop approaches to identify gaps in the discussed issues. This interdisciplinary team of leading experts reviewed the current literature and presented their data to formulate practical guidance on management of patients after COVID-19. The panel of experts also presented recommendations on how to implement the gained knowledge into health care practices.


17 March 2022 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
MGM A Godkov
M A Godkov
ВШВ. В. Шустов
В. В. Шустов
VKVladimir A Korshunov
Vladimir A Korshunov
ФСФ. С. Степанов
Ф. С. Степанов
ABA I Bazhenov
A I Bazhenov
Формирование коллективного иммунитета к SARS-CoV-2 в популяции населения Москвы

30 December 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MGMikhail Godkov
Mikhail Godkov
DODaria Ogarkova
Daria Ogarkova
Vladimir GushchinVladimir Gushchin
Vladimir Gushchin
DKDenis A. Kleymenov
Denis A. Kleymenov
EMElena P. Mazunina
Elena P. Mazunina
AGAlexander L. Gintsburg
Alexander L. Gintsburg
Vaccination against COVID-19 has occurred in Russia for more than two years. According to the Russian official clinical guidelines to maintain tense immunity in the conditions of the ongoing COVID-19 pandemic, it is necessary to use booster immunization six months after primary vaccination or a previous COVID-19 contraction. It is especially important to ensure the maintenance of protective immunity in the elderly, who are at risk of severe courses of COVID-19. Meanwhile, the immunological effectiveness of the booster doses has not been sufficiently substantiated. To investigate the immunogenicity of Sputnik V within the recommended revaccination regimen and evaluate the effectiveness of booster doses, we conducted this study on 3983 samples obtained from individuals previously vaccinated with Sputnik V in Moscow. We analyzed the level of antibodies in BAU/mL three times: (i) six months after primary immunization immediately before the booster (RV), (ii) 3 weeks after the introduction of the first component of the booster (RV1), and (iii) 3 weeks after the introduction of the second component of the booster (RV2). Six months after the primary vaccination with Sputnik V, 95.5% of patients maintained a positive level of IgG antibodies to the receptor-binding domain (RBD) of SARS-CoV-2. The degree of increase in the specific virus-neutralizing antibodies level after revaccination increased with a decrease in their initial level just before the booster dose application. In the group of people with the level of antibodies up to 100 BAU/mL six months after the vaccination, a more than eightfold increase (p < 0.001, Wilcoxon criterion with Bonferroni adjustment) in the level of specific antibodies was observed (Me = 8.84 (IQR: 3.63–30.61)). A significant increase in the IgG level after receiving both the first and the second booster doses occurred at the initial titer level up to 300 BAU/ mL (p < 0.001) in those who did not contract COVID-19 in the past and up to 100 BAU/mL (p < 0.001) in those who were previously infected with SARS-CoV-2. A significant increase in the antibody level after the first dose of the booster was noted for people who had up to 500 BAU/mL (p < 0.05), regardless of the previous COVID-19 infection. Thus, revaccination is most effective in individuals with an antibody level below 500 BAU/mL, regardless of the vaccinee age and COVID-19 contraction. For the first time, it has been shown that a single booster dose of the Sputnik vaccine is sufficient to form a protective immunity in most vaccinees regardless of age and preexisting antibody level.

1 January 2023 in Infectious diseases: News, Opinions, Training
Verified
Journal Article
Closed access
MGMikhail Godkov
Mikhail Godkov
Vladimir GushchinVladimir Gushchin
Vladimir Gushchin
ATA.N. Tsibin
A.N. Tsibin
VSV.V. Shustov
V.V. Shustov
EKE.A. Kasholkina
E.A. Kasholkina
Влияние комплекса противоэпидемических мероприятий на динамику заболеваемости COVID-19 в медицинских организациях психоневрологического профиля